Will performing an aldosterone‑renin ratio (ARR) in a patient who is currently taking spironolactone result in an elevated ARR?

Effect of Spironolactone on Aldosterone-Renin Ratio Testing

No, performing an ARR while a patient is taking spironolactone will NOT produce an elevated ARR—instead, it will likely produce a falsely low or negative ARR due to marked renin elevation, making it unsuitable for screening primary aldosteronism.

Mechanism of Interference

Spironolactone, as a mineralocorticoid receptor antagonist (MRA), causes profound interference with ARR testing through the following mechanism:

• Renin escapes suppression and reaches very high levels in patients taking spironolactone, even in those with confirmed primary aldosteronism 1
• This dramatic renin elevation lowers the ARR ratio, creating false-negative results rather than false-positive/elevated results 2
• The effect is so significant that MRAs have the strongest impact on the renin-angiotensin system among all antihypertensive medications 1

Guideline Recommendations for Medication Management

Withdrawal Requirements

Spironolactone and other MRAs must be withdrawn for at least 4 weeks before ARR testing 3, 4:

• This 4-week withdrawal period also applies to other potassium-sparing diuretics (amiloride, triamterene) and potassium-wasting diuretics 4
• The extended withdrawal period is necessary because these medications raise renin levels, leading to false-negative screening results 3

Practical Screening Approach

The 2025 Endocrine Society guidelines acknowledge real-world challenges:

• For initial screening, discontinuation of habitual therapy is not strictly required, which facilitates increased screening for primary aldosteronism 4
• However, determination of ARR in patients on diuretics and MRAs is best avoided 4
• When tests are performed for diagnostic confirmation (not just screening), patients' medication should be limited to non-interfering agents 4

Alternative Medications During Testing

If blood pressure control is needed during the withdrawal period, switch to non-interfering agents 3, 4:

• Alpha-1 blockers (doxazosin)
• Hydralazine
• Long-acting non-dihydropyridine calcium channel blockers (verapamil, diltiazem) 4

Clinical Pitfalls to Avoid

Common Misinterpretation

• Do not assume spironolactone will elevate the ARR—this is the opposite of what actually occurs 1
• The renin elevation from spironolactone is so pronounced that it can mask even confirmed primary aldosteronism 1

When Withdrawal Is Not Feasible

If spironolactone cannot be safely withdrawn:

• Repeat testing after medication adjustment when clinically appropriate 3
• Consider that a suppressed renin despite MRA therapy would be highly suggestive of primary aldosteronism, as MRAs should stimulate renin 4
• The initial screen may need to be interpreted with extreme caution or considered uninterpretable 4

Additional Testing Considerations

• Correct hypokalemia before testing, as low potassium inhibits aldosterone secretion and causes false-negatives 3, 4
• If initial screening is negative while on interfering medications and pretest probability remains moderate-to-high, repeat testing after appropriate medication withdrawal 3